Evotec SE (EVO)
4.672
+0.15
(+3.37%)
USD |
NASDAQ |
May 31, 16:00
4.685
+0.01
(+0.27%)
After-Hours: 20:00
Evotec Enterprise Value: 1.773B for May 31, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 31, 2024 | 1.773B |
| May 30, 2024 | 1.719B |
| May 29, 2024 | 1.740B |
| May 28, 2024 | 1.840B |
| May 24, 2024 | 1.808B |
| May 23, 2024 | 1.865B |
| May 22, 2024 | 1.950B |
| May 21, 2024 | 1.921B |
| May 20, 2024 | 1.964B |
| May 17, 2024 | 1.978B |
| May 16, 2024 | 2.063B |
| May 15, 2024 | 2.127B |
| May 14, 2024 | 2.084B |
| May 13, 2024 | 2.013B |
| May 10, 2024 | 1.942B |
| May 09, 2024 | 1.985B |
| May 08, 2024 | 1.957B |
| May 07, 2024 | 1.939B |
| May 06, 2024 | 1.960B |
| May 03, 2024 | 1.985B |
| May 02, 2024 | 2.020B |
| May 01, 2024 | 1.978B |
| April 30, 2024 | 1.957B |
| April 29, 2024 | 1.960B |
| April 26, 2024 | 1.896B |
| Date | Value |
|---|---|
| April 25, 2024 | 1.925B |
| April 24, 2024 | 1.971B |
| April 23, 2024 | 2.828B |
| April 22, 2024 | 2.726B |
| April 19, 2024 | 2.623B |
| April 18, 2024 | 2.651B |
| April 17, 2024 | 2.683B |
| April 16, 2024 | 2.602B |
| April 15, 2024 | 2.687B |
| April 12, 2024 | 2.701B |
| April 11, 2024 | 2.651B |
| April 10, 2024 | 2.676B |
| April 09, 2024 | 2.892B |
| April 08, 2024 | 2.906B |
| April 05, 2024 | 2.797B |
| April 04, 2024 | 2.779B |
| April 03, 2024 | 2.828B |
| April 02, 2024 | 2.821B |
| April 01, 2024 | 2.846B |
| March 31, 2024 | 2.892B |
| March 28, 2024 | 2.785B |
| March 27, 2024 | 2.778B |
| March 26, 2024 | 2.650B |
| March 25, 2024 | 2.604B |
| March 22, 2024 | 2.643B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
1.719B
Minimum
May 30 2024
8.644B
Maximum
Dec 15 2021
4.339B
Average
3.899B
Median
May 20 2020
Enterprise Value Benchmarks
| Centogene NV | 63.36M |
| Affimed NV | -1.670M |
| InflaRx NV | -5.829M |
| MorphoSys AG | 2.712B |
| BioNTech SE | 7.581B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -22.45M |
| Revenue (Quarterly) | 226.72M |
| Total Expenses (Quarterly) | 246.49M |
| EPS Diluted (Quarterly) | -0.0652 |
| Gross Profit Margin (Quarterly) | 16.65% |
| Profit Margin (Quarterly) | -9.90% |
| Earnings Yield | -5.93% |
| Normalized Earnings Yield | -5.062 |